Fabien Zoulim，里昂，法国——HBV相关实验室及人物介绍系列

bigben446

Fabien Zoulim，里昂，法国——HBV相关实验室及人物介绍系列

Fabien Zoulim，里昂大学，法国
欧洲最活跃的乙肝临床专家

Lebosse, F. and F. Zoulim (2016). "[Towards new therapeutic concepts to fight against chronic hepatitis B]." Presse Med 45(1): 1-3.
Isorce, N. and B. Testoni, et al. (2016). "Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus." Antiviral Res 130: 36-45.
Plissonnier, M. L. and T. Lahlali, et al. (2016). "Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1  and the Hepatitis C Virus." PLoS Biol 14(3): e1002421.
Chi, H. and P. Arends, et al. (2016). "Flares during long-term entecavir therapy in chronic hepatitis B." J Gastroenterol Hepatol.
Durantel, D. and F. Zoulim (2016). "New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus." J Hepatol 64(1 Suppl): S117-31.
Boyd, A. and S. Maylin, et al. (2016). "Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa." J Gastroenterol Hepatol 31(3): 634-44.
Park, Y. K. and E. S. Park, et al. (2016). "Cleaved c-FLIP mediates the antiviral effect of TNF-alpha against hepatitis B virus by dysregulating hepatocyte nuclear factors." J Hepatol 64(2): 268-77.
Kumar, R. and S. Perez-Del-Pulgar, et al. (2016). "Clinical relevance of the study of hepatitis B virus covalently closed circular DNA." Liver Int 36 Suppl 1: 72-7.
Cottarel, J. and M. L. Plissonnier, et al. (2016). "FIG4 is a hepatitis C virus particle-bound protein implicated in virion morphogenesis and infectivity with cholesteryl ester modulation potential." J Gen Virol 97(1): 69-81.
Velay, A. and H. Jeulin, et al. (2016). "Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy." J Viral Hepat 23(5): 387-98.
Marcellin, P. and F. Zoulim, et al. (2016). "Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France." Dig Dis Sci.
Yuen, M. F. and S. H. Ahn, et al. (2016). "Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations." J Clin Gastroenterol 50(4): 286-94.
Bailly, F. and P. Pradat, et al. (2015). "Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis." Dig Dis 33(4): 613-23.
Laouenan, C. and J. Guedj, et al. (2015). "A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy." CPT Pharmacometrics Syst Pharmacol 4(1): e00008.
Luangsay, S. and M. Gruffaz, et al. (2015). "Early inhibition of hepatocyte innate responses by hepatitis B virus." J Hepatol 63(6): 1314-22.
Liang, T. J. and T. M. Block, et al. (2015). "Present and future therapies of hepatitis B: From discovery to cure." Hepatology 62(6): 1893-908.
Scholtes, C. and R. Kumar, et al. (2015). "Can We Predict Sustained Virologic Response to Interferon alpha Therapy in Patients With Chronic Hepatitis Delta Virus Infection?" Clin Gastroenterol Hepatol 13(13): 2350-2.
Isorce, N. and J. Lucifora, et al. (2015). "Immune-modulators to combat hepatitis B virus infection: From IFN-alpha to novel  investigational immunotherapeutic strategies." Antiviral Res 122: 69-81.
Boyd, A. and S. Maylin, et al. (2015). "Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification." Diagn Microbiol Infect Dis 83(3): 248-51.
Arends, P. and M. J. Sonneveld, et al. (2015). "Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians." Gut 64(8): 1289-95.
Testoni, B. and F. Zoulim (2015). "Liver capsule: Validated and potential novel targets to treat hepatitis B virus." Hepatology 62(5): 1619.
Zoulim, F. and T. J. Liang, et al. (2015). "Hepatitis C virus treatment in the real world: optimising treatment and access to therapies." Gut 64(11): 1824-33.
Pradat, P. and V. Virlogeux, et al. (2015). "Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy." Hepat Mon 15(9): e28879.
Zoulim, F. and G. Carosi, et al. (2015). "Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study." J Hepatol 62(1): 56-63.
Reddy, K. R. and S. Zeuzem, et al. (2015). "Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN):  a randomised, double-blind, non-inferiority phase 3 trial." Lancet Infect Dis 15(1): 27-35.
Charuworn, P. and P. N. Hengen, et al. (2015). "Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate." J Hepatol 62(5): 1033-9.
Villiers, M. B. and J. C. Cortay, et al. (2015). "Protein-peptide arrays for detection of specific anti-hepatitis D virus (HDV) genotype 1, 6, and 8 antibodies among HDV-infected patients by surface plasmon resonance imaging." J Clin Microbiol 53(4): 1164-71.
Zoulim, F. and D. Durantel (2015). "Antiviral therapies and prospects for a cure of chronic hepatitis B." Cold Spring Harb Perspect Med 5(4).
Bailly, F. and V. Virlogeux, et al. (2015). "Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based  regimen - The ANRS CO20-CUPIC study." Clin Res Hepatol Gastroenterol 39(4): 443-50.
Petit, M. A. and P. Berthillon, et al. (2015). "Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases." Clin Res Hepatol Gastroenterol 39(6): 699-704.
Bailly, F. and K. Hartig-Lavie, et al. (2015). "[Treatment of hepatitis C: decisive therapeutic advances]." Rev Prat 65(2): 255-6.
Wang, Q. and P. Sachse, et al. (2015). "T- and B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patients." J Viral Hepat 22(12): 1068-78.
Bailly, F. and K. Hartig-Lavie, et al. (2015). "[Viral hepatitis]." Rev Prat 65(2): 259-68.
Boyd, A. and J. Gozlan, et al. (2015). "Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus." AIDS 29(15): 1963-73.
Boettler, T. and D. Moradpour, et al. (2014). "Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis." J Hepatol 61(3): 696-705.
Boyd, A. and J. Gozlan, et al. (2014). "Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications." Hepatology 60(2): 497-507.
Miailhes, P. and M. Maynard-Muet, et al. (2014). "Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive  HIV-co-infected patients on cART including tenofovir: EMVIPEG study." J Hepatol 61(4): 761-9.
Virlogeux, V. and P. Pradat, et al. (2014). "Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver  disease score." J Viral Hepat 21(9): e98-e107.
Laouenan, C. and P. Marcellin, et al. (2014). "Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients." Antimicrob Agents Chemother 58(9): 5332-41.
Berg, T. and F. Zoulim, et al. (2014). "Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients." J Hepatol 60(4): 715-22.
Hosel, M. and J. Lucifora, et al. (2014). "Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo." Hepatology 59(6): 2110-20.
Yu, D. M. and X. H. Li, et al. (2014). "N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape." J Hepatol 60(3): 515-22.
Hayer, J. and C. Rodriguez, et al. (2014). "Ultradeep pyrosequencing and molecular modeling identify key structural features  of hepatitis B virus RNase H, a putative target for antiviral intervention." J Virol 88(1): 574-82.
Koffi, J. and R. Egounlety, et al. (2014). "Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B." Eur J Gastroenterol Hepatol 26(2): 146-54.
Jammart, B. and M. Michelet, et al. (2013). "Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells." J Virol 87(9): 5065-80.
Maylin, S. and A. Boyd, et al. (2013). "Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus." J Clin Virol 56(4): 306-11.
Svarovskaia, E. S. and M. Curtis, et al. (2013). "Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen." J Viral Hepat 20(2): 131-40.
Zoulim, F. and S. Locarnini (2013). "Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance." Liver Int 33 Suppl 1: 116-24.
Hayer, J. and F. Jadeau, et al. (2013). "HBVdb: a knowledge database for Hepatitis B Virus." Nucleic Acids Res 41(Database issue): D566-70.
Zoutendijk, R. and J. G. Reijnders, et al. (2013). "Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis." Gut 62(5): 760-5.
Zoulim, F. (2013). "Does occult HBV infection have an impact on the evolution of chronic hepatitis C?" J Hepatol 59(4): 646-7.
Lavocat, F. and P. Deny, et al. (2013). "Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy." J Hepatol 59(4): 684-95.
Zoulim, F. and S. Luangsay, et al. (2013). "Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B." Gastroenterology 144(7): 1342-4.
Zoulim, F. and B. Testoni, et al. (2013). "Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies." Clin Gastroenterol Hepatol 11(8): 1011-3.
Lacombe, K. and A. Boyd, et al. (2013). "High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants  among human immunodeficiency virus/hepatitis B-infected patients." Hepatology 58(3): 912-22.
Zoulim, F. (2012). "Are novel combination therapies needed for chronic hepatitis B?" Antiviral Res 96(2): 256-9.
Leroy, V. and L. Serfaty, et al. (2012). "Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver." Liver Int 32(10): 1477-92.
van Breugel, P. C. and E. I. Robert, et al. (2012). "Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates." Hepatology 56(6): 2116-24.
Zoulim, F. and F. Bailly, et al. (2012). "Treatment of human immunodeficiency virus and hepatitis B virus infections." Haemophilia 18 Suppl 4: 34-7.
Zoulim, F. and F. Bailly (2012). "New approaches to the management of hepatitis C in haemophilia in 2012." Haemophilia 18 Suppl 4: 28-33.
Durantel, D. and F. Zoulim (2012). "Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option?" J Hepatol 57(3): 486-9.
Martinet, J. and V. Leroy, et al. (2012). "Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection." Hepatology 56(5): 1706-18.
Thomas, D. and F. Zoulim (2012). "New challenges in viral hepatitis." Gut 61 Suppl 1: i1-5.
Martel, N. and L. Cotte, et al. (2012). "Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape." J Infect Dis 205(11): 1757-61.
Scholtes, C. and V. Icard, et al. (2012). "Standardized one-step real-time reverse transcription-PCR assay for universal detection and quantification of hepatitis delta virus from clinical samples in the presence of a heterologous internal-control RNA." J Clin Microbiol 50(6): 2126-8.
Maylin, S. and A. Boyd, et al. (2012). "Kinetics of hepatitis B surface and envelope antigen and prediction of treatment  response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients." AIDS 26(8): 939-49.
Gish, R. and J. D. Jia, et al. (2012). "Selection of chronic hepatitis B therapy with high barrier to resistance." Lancet Infect Dis 12(4): 341-53.
Billioud, G. and C. Pichoud, et al. (2012). "Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants." J Hepatol 56(6): 1269-75.
Zoulim, F. and S. Locarnini (2012). "Management of treatment failure in chronic hepatitis B." J Hepatol 56 Suppl 1: S112-22.
Scholtes, C. and C. Ramiere, et al. (2012). "High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients." Hepatology 56(1): 39-48.
Le Gal, F. and S. Badur, et al. (2012). "Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins." Arch Virol 157(4): 647-59.
Reddy, K. R. and F. Lin, et al. (2012). "Response-guided and -unguided treatment of chronic hepatitis C." Liver Int 32 Suppl 1: 64-73.
Maylin, S. and A. Boyd, et al. (2012). "Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV  and hepatitis B virus." Clin Vaccine Immunol 19(2): 242-8.
Petersen, J. and V. Ratziu, et al. (2012). "Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study." J Hepatol 56(3): 520-6.
Zoulim, F. (2011). "Hepatitis: Treatment failure in chronic hepatitis B." Nat Rev Gastroenterol Hepatol 8(7): 366-7.
Kitab, B. and F. A. El, et al. (2011). "Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers." J Infect 63(1): 66-75.
Zoutendijk, R. and J. G. Reijnders, et al. (2011). "Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response." Hepatology 54(2): 443-51.
Shukla, R. and J. Yue, et al. (2011). "Proinflammatory cytokine TNF-alpha increases the stability of hepatitis B virus X protein through NF-kappaB signaling." Carcinogenesis 32(7): 978-85.
Obeid, S. and S. S. Printsevskaya, et al. (2011). "Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics." J Antimicrob Chemother 66(6): 1287-94.
Liu, Y. and C. Wang, et al. (2011). "Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection." J Viral Hepat 18(4): e29-39.
Lucifora, J. and S. Arzberger, et al. (2011). "Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection." J Hepatol 55(5): 996-1003.
Zoulim, F. (2011). "Hepatitis B virus resistance to antiviral drugs: where are we going?" Liver Int 31 Suppl 1: 111-6.
Xu, Z. and X. Ren, et al. (2011). "Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients  with mild and severe chronic hepatitis B and acute-on-chronic liver failure." J Gastroenterol 46(3): 391-400.
Vigano, M. and C. Vener, et al. (2011). "Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic  SCT." Bone Marrow Transplant 46(1): 125-31.
Vincent, I. E. and C. Zannetti, et al. (2011). "Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic  cells." PLoS One 6(10): e26315.
Billioud, G. and C. Pichoud, et al. (2011). "The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication." Antiviral Res 92(2): 271-6.
Si-Ahmed, S. N. and P. Pradat, et al. (2011). "Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study." Antiviral Res 92(1): 90-5.
Liu, Y. and C. Wang, et al. (2010). "Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B." Antivir Ther 15(8): 1185-90.
Ndongo, N. and P. Berthillon, et al. (2010). "Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral  response to therapy in patients infected with hepatitis C virus." Hepatology 52(5): 1531-42.
Kahloun, A. and M. Bourliere, et al. (2010). "[Analogs combination therapy in chronic hepatitis B: when and how?]." Gastroenterol Clin Biol 34 Suppl 2: S126-35.
Gauthier, M. and B. Bonnaud, et al. (2010). "Microarray for hepatitis B virus genotyping and detection of 994 mutations along  the genome." J Clin Microbiol 48(11): 4207-15.
Kaur, P. and A. Paliwal, et al. (2010). "DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection." J Infect Dis 202(5): 700-4.
Berg, T. and P. Marcellin, et al. (2010). "Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection." Gastroenterology 139(4): 1207-17.
Ait-Goughoulte, M. and J. Lucifora, et al. (2010). "Innate antiviral immune responses to hepatitis B virus." Viruses 2(7): 1394-410.
Deny, P. and F. Zoulim (2010). "Hepatitis B virus: from diagnosis to treatment." Pathol Biol (Paris) 58(4): 245-53.
Lucifora, J. and I. E. Vincent, et al. (2010). "Hepatitis B virus replication in primary macaque hepatocytes: crossing the species barrier toward a new small primate model." Hepatology 51(6): 1954-60.
Faurie, P. and C. Broussolle, et al. (2010). "Sarcoidosis and hepatitis C: clinical description of 11 cases." Eur J Gastroenterol Hepatol 22(8): 967-72.
Reijnders, J. G. and K. Deterding, et al. (2010). "Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues." J Hepatol 52(4): 493-500.
Ahmed, S. N. and M. Ecochard, et al. (2010). "End points of therapy in chronic hepatitis B." Expert Rev Gastroenterol Hepatol 4(1): 37-49.
Ren, X. and Z. Xu, et al. (2010). "Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis." J Viral Hepat 17(12): 887-95.
Niesters, H. G. and F. Zoulim, et al. (2010). "Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment." Antimicrob Agents Chemother 54(3): 1283-9.
Lucifora, J. and D. Durantel, et al. (2010). "Control of hepatitis B virus replication by innate response of HepaRG cells." Hepatology 51(1): 63-72.
Trepo, C. and F. Zoulim (2009). "[Treatment of hepatitis B: new perspectives]." Gastroenterol Clin Biol 33(8-9): 811-7.
Borgniet, O. and P. Parvaz, et al. (2009). "Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy  for chronic hepatitis B." J Med Virol 81(8): 1336-42.
Bartosch, B. and R. Thimme, et al. (2009). "Hepatitis C virus-induced hepatocarcinogenesis." J Hepatol 51(4): 810-20.
Chaubo, C. and A. Hot, et al. (2009). "Kidney transplant and cryptic hepatitis." Lancet 373(9680): 2082.
Delang, L. and J. Paeshuyse, et al. (2009). "Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development." Hepatology 50(1): 6-16.
Vincent, I. E. and J. Lucifora, et al. (2009). "Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro." Antivir Ther 14(1): 131-5.
Zoulim, F. and D. Durantel, et al. (2009). "Management and prevention of drug resistance in chronic hepatitis B." Liver Int 29 Suppl 1: 108-15.
Liu, Y. and J. J. Zhao, et al. (2009). "Altered expression profiles of microRNAs in a stable hepatitis B virus-expressing cell line." Chin Med J (Engl) 122(1): 10-4.
Covic, A. and D. Abramowicz, et al. (2009). "Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement." Nephrol Dial Transplant 24(3): 719-27.
Chemin, I. and F. Zoulim (2009). "Hepatitis B virus induced hepatocellular carcinoma." Cancer Lett 286(1): 52-9.
Hantz, O. and R. Parent, et al. (2009). "Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells." J Gen Virol 90(Pt 1): 127-35.
Villet, S. and G. Billioud, et al. (2009). "In vitro characterization of viral fitness of therapy-resistant hepatitis B variants." Gastroenterology 136(1): 168-176.e2.
Durantel, D. and F. Zoulim (2009). "Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus." Hepatology 50(6): 1692-5.
Zoulim, F. and S. Locarnini (2009). "Hepatitis B virus resistance to nucleos(t)ide analogues." Gastroenterology 137(5): 1593-608.e1-2.
Liu, Y. and C. M. Wang, et al. (2009). "Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility." Chin Med J (Engl) 122(13): 1585-6.
Santantonio, T. and M. Fasano, et al. (2009). "Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B." Antivir Ther 14(4): 557-65.
Villet, S. and C. Pichoud, et al. (2008). "Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure." J Hepatol 48(5): 747-55.
Zoulim, F. and R. Perrillo (2008). "Hepatitis B: reflections on the current approach to antiviral therapy." J Hepatol 48 Suppl 1: S2-19.
Pawlotsky, J. M. and G. Dusheiko, et al. (2008). "Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach." Gastroenterology 134(2): 405-15.
Zoulim, F. (2008). "[Current data on the treatment of chronic hepatitis B]." Presse Med 37(2 Pt 2): 287-93.
Cooksley, H. and S. Chokshi, et al. (2008). "Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated  with enhanced virus-specific CD4+ T-cell reactivity." Antimicrob Agents Chemother 52(1): 312-20.
Zoulim, F. and S. Radenne, et al. (2008). "Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis." Liver Transpl 14 Suppl 2: S1-7.
Lacombe, K. and J. Gozlan, et al. (2008). "Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients." Antivir Ther 13(5): 705-13.
Fournier, C. and F. Zoulim (2008). "[Combination therapy in chronic hepatitis B]." Gastroenterol Clin Biol 32(1 Pt 2): S42-9.
Raimondo, G. and J. P. Allain, et al. (2008). "Statements from the Taormina expert meeting on occult hepatitis B virus infection." J Hepatol 49(4): 652-7.
Lucifora, J. and D. Durantel, et al. (2008). "Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector." J Gen Virol 89(Pt 8): 1819-28.
Alotte, C. and A. Martin, et al. (2008). "Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro." Antiviral Res 80(3): 280-7.
Soriano, V. and M. Puoti, et al. (2008). "Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel." AIDS 22(12): 1399-410.
Margeridon, S. and S. Carrouee-Durantel, et al. (2008). "Rolling circle amplification, a powerful tool for genetic and functional studies  of complete hepatitis B virus genomes from low-level infections and for directly  probing covalently closed circular DNA." Antimicrob Agents Chemother 52(9): 3068-73.
Carrouee-Durantel, S. and D. Durantel, et al. (2008). "Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants." Antivir Ther 13(3): 381-8.
Bailly, F. and F. Zoulim (2008). "[Treatment of hepatitis B. Therapeutic management]." Gastroenterol Clin Biol 32(5 Pt 2): S172-8.
Soriano, V. and A. S. Perelson, et al. (2008). "Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?" J Antimicrob Chemother 62(1): 1-4.
Thermet, A. and T. Buronfosse, et al. (2008). "DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection." J Gen Virol 89(Pt 5): 1192-201.
Villet, S. and A. Ollivet, et al. (2007). "Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient." J Hepatol 46(3): 531-8.
Sheldon, J. and B. Ramos, et al. (2007). "Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity." J Acquir Immune Defic Syndr 46(3): 279-82.
Zoulim, F. and M. Buti, et al. (2007). "Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?" J Viral Hepat 14 Suppl 1: 29-36.
Fournier, C. and F. Zoulim (2007). "Antiviral therapy of chronic hepatitis B: prevention of drug resistance." Clin Liver Dis 11(4): 869-92, ix.
Thibault, V. and C. Pichoud, et al. (2007). "Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections." J Clin Microbiol 45(12): 3948-53.
Miailhes, P. and M. A. Trabaud, et al. (2007). "Impact of highly active antiretroviral therapy (HAART) on the natural history of  hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion." Clin Infect Dis 45(5): 624-32.
Keeffe, E. B. and S. Zeuzem, et al. (2007). "Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B." Clin Gastroenterol Hepatol 5(8): 890-7.
Zoulim, F. (2007). "Emerging drugs for hepatitis B." Expert Opin Emerg Drugs 12(2): 199-217.
Mrani, S. and I. Chemin, et al. (2007). "Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C." J Med Virol 79(8): 1075-81.
Li, K. and F. Zoulim, et al. (2007). "Critical role of the 36-nucleotide insertion in hepatitis B virus genotype G in core protein expression, genome replication, and virion secretion." J Virol 81(17): 9202-15.
Lazar, C. and D. Durantel, et al. (2007). "Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity." Antiviral Res 76(1): 30-7.
Kay, A. and F. Zoulim (2007). "Hepatitis B virus genetic variability and evolution." Virus Res 127(2): 164-76.
Chapel, C. and C. Garcia, et al. (2007). "Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors." J Gen Virol 88(Pt 4): 1133-43.
Brunelle, M. N. and J. Lucifora, et al. (2007). "In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants." Antimicrob Agents Chemother 51(6): 2240-3.
Marotte, H. and E. Fontanges, et al. (2007). "Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus." Rheumatology (Oxford) 46(1): 97-9.
Durantel, D. and C. Alotte, et al. (2007). "Glucosidase inhibitors as antiviral agents for hepatitis B and C." Curr Opin Investig Drugs 8(2): 125-9.
Durantel, D. and F. Zoulim (2007). "Going towards more relevant cell culture models to study the in vitro replication of serum-derived hepatitis C virus and virus/host cell interactions?" J Hepatol 46(1): 1-5.
Durantel, D. and F. Zoulim (2007). "Learning from HIV: how will drug resistance influence treatment strategies against hepatitis C?" J HIV Ther 12(4): 88-91.
Zoulim, F. (2006). "Hepatitis B virus resistance to entecavir in nucleoside naive patients: Does it exist?" Hepatology 44(6): 1404-7.
Zoulim, F. (2006). "[New virologic tests and their application in management of chronic hepatitis B]." Presse Med 35(2 Pt 2): 317-26.
Lacombe, K. and V. Massari, et al. (2006). "Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV." AIDS 20(3): 419-27.
Diaz, O. and F. Delers, et al. (2006). "Preferential association of Hepatitis C virus with apolipoprotein B48-containing  lipoproteins." J Gen Virol 87(Pt 10): 2983-91.
Tran, N. and R. Berne, et al. (2006). "European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes." J Clin Microbiol 44(8): 2792-800.
Sheldon, J. and B. Rodes, et al. (2006). "Mutations affecting the replication capacity of the hepatitis B virus." J Viral Hepat 13(7): 427-34.
Lobato, C. and J. Tavares-Neto, et al. (2006). "Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: epidemiologic and biomolecular study." J Gastroenterol Hepatol 21(5): 863-8.
Lacombe, K. and A. Ollivet, et al. (2006). "A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient." AIDS 20(17): 2229-31.
Zoulim, F. (2006). "Antiviral therapy of chronic hepatitis B." Antiviral Res 71(2-3): 206-15.
Zoulim, F. (2006). "[Definitions of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]." Gastroenterol Clin Biol 30(10 Pt 2): 3S9-11.
Zoulim, F. (2006). "In vitro models for studying hepatitis B virus drug resistance." Semin Liver Dis 26(2): 171-80.
Zoulim, F. (2006). "New nucleic acid diagnostic tests in viral hepatitis." Semin Liver Dis 26(4): 309-17.
Zoulim, F. and T. Poynard, et al. (2006). "A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine." J Viral Hepat 13(4): 278-88.
Chapel, C. and C. Garcia, et al. (2006). "Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles." J Gen Virol 87(Pt 4): 861-71.
Narayan, R. and T. Buronfosse, et al. (2006). "Rise in gamma interferon expression during resolution of duck hepatitis B virus infection." J Gen Virol 87(Pt 11): 3225-32.
Zoulim, F. (2006). "Entecavir: a new treatment option for chronic hepatitis B." J Clin Virol 36(1): 8-12.
Escuret, V. and A. Martin, et al. (2006). "Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy  in a subgenomic replicon system." Antimicrob Agents Chemother 50(12): 3984-91.
Villet, S. and C. Pichoud, et al. (2006). "Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient." Gastroenterology 131(4): 1253-61.
Jacquard, A. C. and M. N. Brunelle, et al. (2006). "In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine." Antimicrob Agents Chemother 50(3): 955-61.
Durantel, D. and M. N. Brunelle, et al. (2005). "Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing." J Clin Virol 34 Suppl 1: S34-43.
Poynard, T. and F. Zoulim, et al. (2005). "Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection." Am J Gastroenterol 100(9): 1970-80.
Bizollon, T. and P. Pradat, et al. (2005). "Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C." Am J Transplant 5(8): 1909-13.
Margeridon, S. and A. Lachaux, et al. (2005). "A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus." J Gen Virol 86(Pt 6): 1687-93.
Escuret, V. and F. Zoulim (2005). "[Treatment of hepatitis C]." Rev Prat 55(6): 633-45.
Khattab, E. and I. Chemin, et al. (2005). "Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy." J Clin Virol 33(2): 150-7.
Lacombe, K. and J. Gozlan, et al. (2005). "Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate." AIDS 19(9): 907-15.
Nissen, M. J. and E. Fontanges, et al. (2005). "Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon." Rheumatology (Oxford) 44(8): 1016-20.
Zoulim, F. (2005). "Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models." J Antimicrob Chemother 55(5): 608-11.
Zoulim, F. (2005). "New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA." J Hepatol 42(3): 302-8.
Bizollon, T. and M. Adham, et al. (2005). "Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C." Transplantation 79(3): 325-9.
Robaczewska, M. and R. Narayan, et al. (2005). "Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA)." J Hepatol 42(2): 180-7.
Bang, G. and K. H. Kim, et al. (2005). "Effect of mutating the two cysteines required for HBe antigenicity on hepatitis B virus DNA replication and virion secretion." Virology 332(1): 216-24.
Werle, B. and K. Cinquin, et al. (2004). "Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy." J Viral Hepat 11(1): 74-83.
Rocca, P. and J. S. El, et al. (2004). "[Imatinib mesylate-induced acute cytolytic hepatitis]." Gastroenterol Clin Biol 28(10 Pt 1): 918-9.
Zoulim, F. (2004). "Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection." Antiviral Res 64(1): 1-15.
Rocca, P. and L. Codes, et al. (2004). "[Autoimmunization induced by interferon alpha therapy in chronic hepatitis C]." Gastroenterol Clin Biol 28(11): 1173-6.
Durantel, D. and S. Carrouee-Durantel, et al. (2004). "A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus." Hepatology 40(4): 855-64.
Zoulim, F. (2004). "Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?" Antivir Chem Chemother 15(6): 299-305.
Vuillermoz, I. and E. Khattab, et al. (2004). "Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy." J Med Virol 74(1): 41-53.
Seve, P. and P. Renaudier, et al. (2004). "Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional  study in Lyon, France." Eur J Gastroenterol Hepatol 16(12): 1361-5.
Jeantet, D. and I. Chemin, et al. (2004). "Cloning and expression of surface antigens from occult chronic hepatitis B virus  infections and their recognition by commercial detection assays." J Med Virol 73(4): 508-15.
Locarnini, S. and A. Hatzakis, et al. (2004). "Management of antiviral resistance in patients with chronic hepatitis B." Antivir Ther 9(5): 679-93.
Jacquard, A. C. and M. Nassal, et al. (2004). "Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection." Antimicrob Agents Chemother 48(7): 2683-92.
Werle-Lapostolle, B. and S. Bowden, et al. (2004). "Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy." Gastroenterology 126(7): 1750-8.
Cova, L. and F. Zoulim (2004). "Duck hepatitis B virus model in the study of hepatitis B virus." Methods Mol Med 96: 261-8.
Hantz, O. and F. Zoulim (2004). "Duck hepatitis B virus primary hepatocyte culture model." Methods Mol Med 96: 189-97.
Trepo, C. and M. Maynard, et al. (2003). "Perspectives on therapy of hepatitis B." J Hepatol 39 Suppl 1: S220-3.
Zoulim, F. (2003). "Hepatitis B virus resistance to antivirals: clinical implications and management." J Hepatol 39 Suppl 1: S133-8.
Villeneuve, J. P. and D. Durantel, et al. (2003). "Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient." J Hepatol 39(6): 1085-9.
Sablon, E. and F. Shapiro, et al. (2003). "Early detection of hepatitis B drug resistance: implications for patient management." Expert Rev Mol Diagn 3(5): 535-47.
Parekh, S. and F. Zoulim, et al. (2003). "Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants." J Virol 77(12): 6601-12.
Zoulim, F. (2003). "Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation?" J Hepatol 38(6): 850-2.
Seigneres, B. and P. Martin, et al. (2003). "Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model." Antimicrob Agents Chemother 47(6): 1842-52.
Salmon-Ceron, D. and R. Lassalle, et al. (2003). "Interferon-ribavirin in association with stavudine has no impact on plasma human  immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial." Clin Infect Dis 36(10): 1295-304.
Rocca, P. and F. Bailly, et al. (2003). "[Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients]." Gastroenterol Clin Biol 27(3 Pt 1): 294-9.
Le Guerhier, F. and A. Thermet, et al. (2003). "Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model." J Hepatol 38(3): 328-34.
Bizollon, T. and S. N. Ahmed, et al. (2003). "Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence." Gut 52(2): 283-7.
Thermet, A. and C. Rollier, et al. (2003). "Progress in DNA vaccine for prophylaxis and therapy of hepatitis B." Vaccine 21(7-8): 659-62.
Zoulim, F. and M. Chevallier, et al. (2003). "Clinical consequences of hepatitis C virus infection." Rev Med Virol 13(1): 57-68.
Durantel, D. and V. Escuret, et al. (2003). "Current and emerging therapeutic approaches to hepatitis C infection." Expert Rev Anti Infect Ther 1(3): 441-54.
Zoulim, F. (2003). "[New therapeutic advances in chronic hepatitis B]." Gastroenterol Clin Biol 27(2): 151-3.
Zoulim, F. (2002). "Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance." Semin Liver Dis 22 Suppl 1: 23-31.
Lok, A. S. and F. Zoulim, et al. (2002). "Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay." J Clin Microbiol 40(10): 3729-34.
Zoulim, F. (2002). "[Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment]." Gastroenterol Clin Biol 26 Spec No 2: B225-30.
Bailly, F. and F. Zoulim (2002). "[Chronic hepatitis B: natural history and treatments]." Gastroenterol Clin Biol 26(5): 492-500.
Zoulim, F. (2002). "A preliminary benefit-risk assessment of lamivudine for the treatment of chronic  hepatitis B virus infection." Drug Saf 25(7): 497-510.
Jeantet, D. and I. Chemin, et al. (2002). "Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient." Hepatology 35(5): 1215-24.
Zoulim, F. (2002). "[Toward the expected development of therapeutic combinations in hepatitis B?]." Gastroenterol Clin Biol 26(1): 107-8.
Zoulim, F. (2002). "Quantification and genotyping in management of chronic hepatitis B and C." Virus Res 82(1-2): 45-52.
Delmas, J. and O. Schorr, et al. (2002). "Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro." Antimicrob Agents Chemother 46(2): 425-33.
Serfaty, L. and D. Thabut, et al. (2001). "Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study." Hepatology 34(3): 573-7.
Zoulim, F. and B. Werle (2001). "[Current knowledge on chronic hepatitis B therapy]." Gastroenterol Clin Biol 25(4 Suppl): B143-51.
Wartelle-Bladou, C. and J. Lafon, et al. (2001). "Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection." J Hepatol 34(5): 774-9.
Borel, C. and O. Schorr, et al. (2001). "Initial amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of embryonic duck hepatocytes is increased by cell cycle progression." Hepatology 34(1): 168-79.
Zoulim, F. (2001). "Detection of hepatitis B virus resistance to antivirals." J Clin Virol 21(3): 243-53.
Chemin, I. and F. Zoulim, et al. (2001). "High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology." J Hepatol 34(3): 447-54.
Querenghi, F. and Q. Yu, et al. (2001). "Evolution of hepatitis C virus genome in chronically infected patients receiving  ribavirin monotherapy." J Viral Hepat 8(2): 120-31.
Le Guerhier, F. and C. Pichoud, et al. (2001). "Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus." Antimicrob Agents Chemother 45(4): 1065-77.
Seigneres, B. and S. Aguesse-Germon, et al. (2001). "Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo." J Hepatol 34(1): 114-22.
Bain, C. and A. Fatmi, et al. (2001). "Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection." Gastroenterology 120(2): 512-24.
Merle, P. and C. Trepo, et al. (2001). "Current management strategies for hepatitis B in the elderly." Drugs Aging 18(10): 725-35.
Zoulim, F. (2001). "Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models." Antivir Chem Chemother 12 Suppl 1: 131-42.
Pichoud, C. and F. Berby, et al. (2000). "Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B." J Hepatol 32(2): 307-16.
Stuyver, L. and C. Van Geyt, et al. (2000). "Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy." J Clin Microbiol 38(2): 702-7.
Stuyver, L. and S. De Gendt, et al. (2000). "A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness." J Gen Virol 81(Pt 1): 67-74.
Le Guerhier, F. and C. Pichoud, et al. (2000). "Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model." Antimicrob Agents Chemother 44(1): 111-22.
Zoulim, F. (2000). "[Long-term treatment with lamivudine for chronic hepatitis B]." Gastroenterol Clin Biol 24(12): 1153-4.
Zoulim, F. and C. Trepo (2000). "Is lamivudine effective on precore/core promoter mutants of hepatitis B virus?" Hepatology 32(5): 1172-4.
Nafa, S. and S. Ahmed, et al. (2000). "Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B." Hepatology 32(5): 1078-88.
Grandjacques, C. and P. Pradat, et al. (2000). "Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity." J Hepatol 33(3): 430-9.
Querenghi, F. and F. Zoulim (2000). "[Hepatitis C virus]." Rev Prat 50(10): 1060-5.
Hantz, O. and J. L. Kraus, et al. (2000). "Design and evaluation of hepatitis B virus inhibitors." Curr Pharm Des 6(5): 503-23.
Seigneres, B. and C. Pichoud, et al. (2000). "Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B." J Infect Dis 181(4): 1221-33.
Zoulim, F. (1999). "Hepatitis C virus infection in special groups." J Hepatol 31 Suppl 1: 130-5.
Zoulim, F. (1999). "Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies." Antiviral Res 44(1): 1-30.
Broussolle, C. and M. P. Steineur, et al. (1999). "[Hepatitis C virus infection and thyroid diseases]." Rev Med Interne 20(9): 766-73.
Zoulim, F. and C. Trepo (1999). "New antiviral agents for the therapy of chronic hepatitis B virus infection." Intervirology 42(2-3): 125-44.
Romand, F. and M. Michallet, et al. (1999). "[Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B]." Gastroenterol Clin Biol 23(6-7): 770-4.
Hantz, O. and C. Perigaud, et al. (1999). "The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo." Antiviral Res 40(3): 179-87.
Pichoud, C. and B. Seigneres, et al. (1999). "Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance." Hepatology 29(1): 230-7.
Trepo, C. and F. Zoulim, et al. (1999). "Viral hepatitis." Curr Opin Infect Dis 12(5): 481-90.
Zoulim, F. (1999). "[Vaccination against hepatitis B virus: current data]." Med Trop (Mars) 59(4 Pt 2): 503-7.
Habersetzer, F. and F. Zoulim, et al. (1998). "Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha." J Viral Hepat 5(6): 407-14.
Zoulim, F. and C. Trepo (1998). "Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy." J Hepatol 29(1): 151-68.
Zoulim, F. and J. Haem, et al. (1998). "Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients." J Viral Hepat 5(3): 193-8.
Aguesse-Germon, S. and S. H. Liu, et al. (1998). "Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication." Antimicrob Agents Chemother 42(2): 369-76.
Hantz, O. and C. Borel, et al. (1997). "Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles." Antimicrob Agents Chemother 41(11): 2579-81.
Gouillat, C. and D. Manganas, et al. (1997). "Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma." J Hepatol 26(6): 1324-30.
Dumortier, J. and S. Durupt, et al. (1997). "[Favorable course of hepatitis B virus reactivation with hepatocellular insufficiency by a treatment combining corticoids, foscarnet and ganciclovir]." Gastroenterol Clin Biol 21(12): 982-6.
Zoulim, F. and C. Trepo (1997). "[Effects and risks of prolonged antiviral treatments: the example of chronic hepatitis B]." Gastroenterol Clin Biol 21(11): 843-7.
Marcellin, P. and J. M. Metreau, et al. (1996). "[Treatment of chronic viral hepatitis]." Ann Gastroenterol Hepatol (Paris) 32(2): 85-7.
Zoulim, F. and X. Zhang, et al. (1996). "Heterogeneity of hepatitis B virus (HBV) core gene in a patient with HBV-associated cirrhosis and serum negativity for anti-HBc." J Hepatol 24(2): 155-60.
Zoulim, F. and E. Dannaoui, et al. (1996). "2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo." Antimicrob Agents Chemother 40(2): 448-53.
Zhang, X. and F. Zoulim, et al. (1996). "Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B." J Med Virol 48(1): 8-16.
Zoulim, F. and F. Capel, et al. (1995). "[Clinical and virological evaluation of the detection of pre-S1 and pre-S2 antigens in serum from patients with chronic hepatitis B]." Gastroenterol Clin Biol 19(12): 970-5.
Lamelin, J. P. and F. Zoulim, et al. (1995). "Lymphotropism of hepatitis B and C viruses: an update and a newcomer." Int J Clin Lab Res 25(1): 1-6.
Zoulim, F. and J. Saputelli, et al. (1994). "Woodchuck hepatitis virus X protein is required for viral infection in vivo." J Virol 68(3): 2026-30.
Chemin, I. and C. Vermot-Desroches, et al. (1994). "Selective detection of human hepatitis B virus surface and core antigens in peripheral blood mononuclear cell subsets by flow cytometry." J Viral Hepat 1(1): 39-44.
Petit, M. A. and F. Zoulim, et al. (1994). "PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B." J Hepatol 20(1): 47-56.
Zoulim, F. and C. Seeger (1994). "Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase." J Virol 68(1): 6-13.
Wang, G. H. and F. Zoulim, et al. (1994). "Role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses." J Virol 68(12): 8437-42.
Zoulim, F. and C. Trepo (1994). "Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications." J Hepatol 21(2): 142-4.
Causse, X. and H. Godinot, et al. (1993). "Simultaneous steroids/interferon therapy in chronic hepatitis B." J Hepatol 17(1): 128-9.
Trepo, C. and F. Zoulim, et al. (1993). "Diagnostic markers of viral hepatitis B and C." Gut 34(2 Suppl): S20-5.
Bouffard, P. and J. P. Lamelin, et al. (1992). "Phytohemagglutinin and concanavalin A activate hepatitis B virus in peripheral blood mononuclear cells of patients with chronic hepatitis B virus infection." J Med Virol 37(4): 255-62.
Zoulim, F. and L. Mimms, et al. (1992). "New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection." J Clin Microbiol 30(5): 1111-9.
Gaudin, J. L. and X. Causse, et al. (1992). "[Recovery of chronic hepatitis B- delta infection by zidovudine and recombinant interferon alpha combination therapy in a patient with Kaposi's sarcoma associated with HIV infection]." Gastroenterol Clin Biol 16(5): 468-72.
Chemin, I. and C. Vermot-Desroches, et al. (1992). "Selective detection of human hepatitis B virus surface and core antigens in some  peripheral blood mononuclear cell subsets by flow cytometry." J Clin Lab Immunol 38(2): 63-71.
Petit, M. A. and F. Capel, et al. (1992). "PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell response." Arch Virol Suppl 4: 105-12.
Causse, X. and H. Godinot, et al. (1991). "Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis." Gastroenterology 101(2): 497-502.
Normand, J. C. and F. Zoulim, et al. (1991). "Favorable outcome in fulminating hepatitis associated with native anti-DNA antibodies." Hepatogastroenterology 38(1): 86-7.
Chemin, I. and I. Baginski, et al. (1991). "Correlation between HBV DNA detection by polymerase chain reaction and Pre-S1 antigenemia in symptomatic and asymptomatic hepatitis B virus infections." J Med Virol 33(1): 51-7.
Li, J. and S. Tong, et al. (1990). "Rapid detection and further characterization of infection with hepatitis B virus  variants containing a stop codon in the distal pre-C region." J Gen Virol 71 ( Pt 9): 1993-8.
Bouffard, P. and J. P. Lamelin, et al. (1990). "Different forms of hepatitis B virus DNA and expression of HBV antigens in peripheral blood mononuclear cells in chronic hepatitis B." J Med Virol 31(4): 312-7.
Petit, M. A. and F. Zoulim, et al. (1990). "Variable expression of preS1 antigen in serum during chronic hepatitis B virus infection: an accurate marker for the level of hepatitis B virus replication." Hepatology 11(5): 809-14.
Zoulim, F. and J. P. Lamelin, et al. (1990). "[Clinical implications of interactions between hepatitis B virus and mononuclear  leukocytes]." Gastroenterol Clin Biol 14(3): 255-62.
Trepo, C. and I. Chemin, et al. (1990). "Possible prevention of chronic hepatitis B by early interferon therapy." J Hepatol 11 Suppl 1: S95-9.
Zoulim, F. and L. Vitvitski, et al. (1989). "[Significance of the expression of pre-S proteins in mononuclear blood cells in chronic hepatitis caused by the hepatitis B virus]." Gastroenterol Clin Biol 13(8-9): 707-11.